• News
  • BioTech

Orexigen's loss mounts

Orexigen Therapeutics (Nasdaq: OREX) lost 23 cents per share in the first quarter of 2014, wider than the year-ago loss of 21 cents and deeper than Wall Street expectations of a 20-cent loss.

The loss at the company, which specializes in treatments for obesity, was prompted by rising operating expenses despite relatively flat earnings.

Operating expenses increased to $24.0 million in first quarter of 2014 from $20.3 million during the similar period last year, mostly due to higher raw materials, inventory and manufacturing-related expenses, and salaries and personnel related costs. Research and development expenses rose 12 percent during the year to $17 million. Overhead expenses rose 37.5 percent to $7 million, but revenues remained flat at roughly $900,000.

Wall Street’s Zacks Research predicts the firm will show some improvements this year as it expects to gain $100 million in Takeda after the approval of its NB32 treatment with strong possibilities for foreign sales, but it also faces stiff competition from other obesity treatments.

User Response
0 UserComments

Orexigen Therapeutics Inc.

Company Website

3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037

Orexigen Therapeutics Inc. Executive(s):

Michael Narachi

  • Chief Executive Officer, President